Singular Genomics to Report First Quarter 2023 Financial Results on May 9, 2023
Singular Genomics Systems, Inc. (Nasdaq: OMIC) announced it will report its Q1 2023 financial results after market close on May 9, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
The company specializes in next-generation sequencing and multiomics technologies, with the G4 Sequencing Platform available commercially, enabling fast and accurate genomic sequencing. Additionally, the PX system is under development, focusing on in situ readouts for RNA and proteins in cells and tissues.
For investors interested in the conference call, a live and archived webcast can be accessed through the company’s investor portal.
- Development of advanced sequencing technologies like the G4 Sequencing Platform and PX system may enhance market position.
- Upcoming Q1 2023 results could provide insights into future growth and operational efficiency.
- None.
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the Presentations & Events section.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.
Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Singular Genomics report its Q1 2023 financial results?
What technologies does Singular Genomics focus on?
What time will the Singular Genomics conference call start?
How can I listen to the Singular Genomics conference call?
